

Emyria to accelerate drug development with \$5m strategic investment from Tattarang

Highlights:

- Tattarang to invest \$5m in Emyria via share placement
- Tattarang is one of Australia's largest private investment groups and is owned by the Forrest family.
- Funds raised will be used to accelerate synthetic cannabinoid registration programs with the TGA and FDA, and advance Emyria's novel MDMA-analogue development program with the University of Western Australia.
- For further information please visit tattarang.com

Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed drug development and care delivery company, is pleased to announce a successful \$5 million share placement to strategic investor Tattarang (**Placement**).

Under the Placement, a total of 20 million shares will be issued to Tattarang (or its nominee) at A\$0.25 per share.

Following completion of the Placement, Tattarang will hold an interest of approximately 7.3% in Emyria.

As part of the Placement, Tattarang (or its nominee) will also be issued 10 million options in Emyria (**Options**). The Options will have an exercise price of A\$0.40 per Option and an expiry date of 5.00pm (AWST) 2 years from the date of issue. The Options will be issued for no additional consideration.

Tattarang Chief Investment Officer John Hartman remarked on the investment saying, "Emyria's investment in industry-leading data collection at the front-line of care will allow it to innovate faster and help bring new treatments to those who need them, faster and more cost effectively."

"We believe evidence based, and properly registered, medicinal cannabis and novel psychedelic treatments have massive growth potential across global healthcare jurisdictions."

Emyria's data driven approach positions it strongly to lead the accelerated development and registration of new treatment options that can potentially benefit millions of patients."

emyria

Emyria's Managing Director, Dr. Michael Winlo, said: "We are delighted to receive Tattarang's strong support with this placement.

Tattarang shares our long-term vision to accelerate the development and registration of medicines that can transform the lives of millions of people around the world living with conditions for which current therapies are either ineffective, cause unwanted side effects or are yet to be created.

Emyria is the only ASX-listed company that controls patient-treating clinics and a clinical-trial-grade data system and uses these assets to accelerate the development and registration of new drugs, digital technologies and care models.

Our current leading programs cover synthetic cannabinoid-based pharmaceuticals, MDMA-assisted therapy and novel psychedelic drug development. We are very pleased to welcome Tattarang to be part of this next phase of growth"

Placement details

The Placement shares will be issued utilising the Company's existing placement capacity under ASX Listing Rule 7.1A. The issue price of A\$0.25 per Placement share meets the requirement in ASX Listing Rule 7.1A.3.

The Options will be issued utilising the Company's existing placement capacity under ASX Listing Rule 7.1.

The Placement shares and the Options issue is expected to occur on Wednesday, 24 November 2021.

An Appendix 3B (Proposed issue of securities) has been released in relation to this announcement.

A copy of Tattarang's media release in relation to their investment in Emyria is attached to this release.

This announcement has been approved and authorised for release by the Board of Emyria Limited.

For further information on **Emyria**, please contact:

Dr. Michael Winlo
Managing Director
1300 436 363
mwinlo@emyria.com

Lexi O'Halloran
Media/Investor Relations
+ 61 (0) 404 577 076

lexi@janemorganmanagement.com.au

Andrew Williams
Media Relations
+61 (0) 412 614 125

andrew@profilemedia.com.au

For further information on **Tattarang**, please contact:

Andrew Bennett
M +61 427 782 503
P +61 8 6460 4949
E abennett@tattarang.com



About Emyria (www.emyria.com)

Emyria Limited is a data-backed clinical drug development and care delivery company focused on accelerating treatment development and improving patient care.

Emyria's Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria's drug development programs are informed by insights generated from extensive analysis of **Emyria Data** - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria's independent clinical services (**Emerald Clinics** - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

About Tattarang (www.tattarang.com)

Tattarang is one of Australia's largest private investment groups and is owned by the Forrest family. Its investment portfolio spans across agri-food, energy, resources, property, lifestyle and healthtech.

Further information can be found at tattarang.com.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.



22 November 2021

Tattarang invests in Australian medicinal cannabis innovator Emyria

Tattarang is investing in the future of healthcare technology and the development of registered medicinal cannabis and novel treatments with the announcement of a strategic placement in data-backed clinical drug developer and care provider Emyria Limited (ASX: EMD).

Perth-based Emyria is leading several drug development programs backed by their proprietary clinical evidence, including the development and registration of synthetically produced cannabinoids and psychedelics.

Emyria operates in the clinical pharmaceutical space and is the only ASX-listed company that controls patient-treating clinics, a clinical-trial-grade data system and uses these assets to accelerate the development and registration of treatments for patients with unmet needs.

Despite increased access to medicinal cannabis in many countries, including Australia, a lack of clinical data is constraining further commercialisation and there are very few registered treatment products.

Emyria is filling this information void by using a unique, patient-centric and data driven approach to drug development. The company has one of the world's largest, real-world evidence (RWE) patient registries tracking dose responses to pharmaceutical-grade medicines and is leveraging this data to advance the development and registration of novel cannabinoid treatments.

Emyria operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from consenting patients. Emyria's subsidiary company, Emerald Clinics, has seven sites in Australia and has treated more than 5,000 patients – underpinned by a data system that has already gathered millions of data points.

Using this model, Emyria has already launched 2 patent-backed, synthetic cannabinoid drug development programs targeting the major global markets of mental health and irritable bowel syndrome, with further programs expected targeting TGA and FDA registrations.

In addition, Emyria is advancing several MDMA-based programs including an MDMA-assisted therapy trial for Post-Traumatic Stress Disorder (PTSD) as well as evaluating a library of novel MDMA analogues in partnership with the University of Western Australia with the potential to become treatments for a range of psychiatric and neurological disorders.

Tattarang Chief Investment Officer John Hartman said Emyria's investment in industry-leading data collection at the front-line of care will allow it to innovate faster and help bring new treatments to those who need them, faster and more cost effectively.



“We believe evidence based, registered medicinal cannabis and novel psychedelic treatments have massive growth potential across global healthcare jurisdictions,” Mr Hartman said.

“Emyria’s data driven approach positions it strongly to lead the accelerated development and registration of new treatment options that can potentially benefit millions of patients.”

Emyria’s Managing Director Dr Michael Winlo welcomed Tattarang’s investment and said it will assist the company realise the next phase of its growth strategy, with multiple programs progressing towards registration in Australia and the US.

“Emyria has been working diligently to collate one of the largest clinical grade cannabinoid data-sets in the world. We believe this will lead to the discovery of the next generation of treatments and care models in medicinal cannabis,” Dr Winlo said

“Emyria’s assets also allow us to evaluate emerging treatments such as psychedelic-assisted therapies, which have great potential but require further investment and innovation in new drugs, digital technologies and care models. We are very pleased to welcome Tattarang to be part of this next phase of growth.

“Our vision is to develop medicines and treatments that can transform the lives of millions of people around the world living with chronic pain, autism, post-traumatic stress disorder, insomnia, IBS and countless other conditions for which current therapies are either ineffective, cause unwanted side effects or are yet to be created.”

In October 2021, Emyria secured access to one of the world’s most sophisticated data platforms after joining Palantir’s Foundry Builders Program.

The scheme, run by major software company Palantir Technologies, gives select companies access to powerful and highly secure data integration and analysis software that’s typically only available to major enterprises.

ENDS

Editors Notes

Tattarang is one of Australia’s largest private investment groups and is owned by the Forrest family. Its investment portfolio spans across agri-food, energy, resources, property, lifestyle and healthtech.

Further information can be found at tattarang.com.

Media contact

Andrew Bennett
M +61 427 782 503
P +61 8 6460 4949
E abennett@tattarang.com